Medicago’s COVID-19 Vaccine Shows Positive PI Results, Now Gearing Up for PII, PIII Studies

Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on November 10 that its investigational COVID-19 vaccine candidate (MT-2766) has demonstrated positive interim results in a PI clinical study carried out in Canada for the prevention of the disease. Medicago...read more